These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22998776)

  • 21. Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma.
    So YK; Son YI; Baek CH; Jeong HS; Chung MK; Ko YH
    Ann Surg Oncol; 2012 Mar; 19(3):990-5. PubMed ID: 21879263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
    Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
    Carvalho DP; Ferreira AC
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression.
    Kogai T; Curcio F; Hyman S; Cornford EM; Brent GA; Hershman JM
    J Endocrinol; 2000 Oct; 167(1):125-35. PubMed ID: 11018760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.
    Franzoni A; Dima M; D'Agostino M; Puppin C; Fabbro D; Loreto CD; Pandolfi M; Puxeddu E; Moretti S; Celano M; Bruno R; Filetti S; Russo D; Damante G
    Thyroid; 2009 Mar; 19(3):247-55. PubMed ID: 19207009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF
    Hernandez BY; Rahman M; Loo LWM; Chan OTM; Horio D; Morita S; Bryant-Greenwood G
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):183-194. PubMed ID: 32995956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells.
    Xu S; Cheng X; Wu J; Wang Y; Wang X; Wu L; Yu H; Bao J; Zhang L
    J Mol Cell Biol; 2022 Jan; 13(11):791-807. PubMed ID: 34751390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas.
    Gérard AC; Daumerie C; Mestdagh C; Gohy S; De Burbure C; Costagliola S; Miot F; Nollevaux MC; Denef JF; Rahier J; Franc B; De Vijlder JJ; Colin IM; Many MC
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4977-83. PubMed ID: 14557483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer.
    Zhang J; Zhao A; Jia X; Li X; Liang Y; Liu Y; Xie X; Qu X; Wang Q; Zhang Y; Gao R; Yu Y; Yang A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes.
    Morgan SJ; Neumann S; Marcus-Samuels B; Gershengorn MC
    Thyroid; 2016 Dec; 26(12):1794-1803. PubMed ID: 27638195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.
    Mian C; Barollo S; Pennelli G; Pavan N; Rugge M; Pelizzo MR; Mazzarotto R; Casara D; Nacamulli D; Mantero F; Opocher G; Busnardo B; Girelli ME
    Clin Endocrinol (Oxf); 2008 Jan; 68(1):108-16. PubMed ID: 17854396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thyrotropin, but Not Thyroid-Stimulating Antibodies, Induces Biphasic Regulation of Gene Expression in Human Thyrocytes.
    Jang D; Morgan SJ; Klubo-Gwiezdzinska J; Banga JP; Neumann S; Gershengorn MC
    Thyroid; 2020 Feb; 30(2):270-276. PubMed ID: 31805824
    [No Abstract]   [Full Text] [Related]  

  • 34. Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors.
    Hoffmann S; Hofbauer LC; Scharrenbach V; Wunderlich A; Hassan I; Lingelbach S; Zielke A
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6139-45. PubMed ID: 15579770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
    Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
    Riesco-Eizaguirre G; Gutiérrez-Martínez P; García-Cabezas MA; Nistal M; Santisteban P
    Endocr Relat Cancer; 2006 Mar; 13(1):257-69. PubMed ID: 16601293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
    Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
    Oh JM; Ahn BC
    Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
    Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
    Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.